%0 Randomized Controlled Trial
%T Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial.
%A Ranjan T
%A Sengupta S
%A Glantz MJ
%A Green RM
%A Yu A
%A Aregawi D
%A Chaudhary R
%A Chen R
%A Zuccarello M
%A Lu-Emerson C
%A Moulding HD
%A Belman N
%A Glass J
%A Mammoser A
%A Anderson M
%A Valluri J
%A Marko N
%A Schroeder J
%A Jubelirer S
%A Chow F
%A Claudio PP
%A Alberico AM
%A Lirette ST
%A Denning KL
%A Howard CM
%J Cell Rep Med
%V 4
%N 5
%D 2023 05 16
%M 37137304
%F 16.988
%R 10.1016/j.xcrm.2023.101025
%X Therapy-resistant cancer stem cells (CSCs) contribute to the poor clinical outcomes of patients with recurrent glioblastoma (rGBM) who fail standard of care (SOC) therapy. ChemoID is a clinically validated assay for identifying CSC-targeted cytotoxic therapies in solid tumors. In a randomized clinical trial (NCT03632135), the ChemoID assay, a personalized approach for selecting the most effective treatment from FDA-approved chemotherapies, improves the survival of patients with rGBM (2016 WHO classification) over physician-chosen chemotherapy. In the ChemoID assay-guided group, median survival is 12.5 months (95% confidence interval [CI], 10.2-14.7) compared with 9 months (95% CI, 4.2-13.8) in the physician-choice group (p = 0.010) as per interim efficacy analysis. The ChemoID assay-guided group has a significantly lower risk of death (hazard ratio [HR] = 0.44; 95% CI, 0.24-0.81; p = 0.008). Results of this study offer a promising way to provide more affordable treatment for patients with rGBM in lower socioeconomic groups in the US and around the world.